Related Articles
A novel CD44v6 targeting antibody fragment with improved tumor-to-blood ratio
PROGRESS IN RADIOIMMUNOTHERAPY OF HEAD AND NECK-CANCER (REVIEW)
Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin
Preclinical evaluation of a novel engineered recombinant human anti-CD44v6 antibody for potential use in radio-immunotherapy
Biodistribution of 211At labeled HER-2 binding affibody molecules in mice